Focused Disease Areas for a Stronger Business Model

A Novartis focused disease areas strategy with supporting commercial strength was outlined for investors at 2024 J.P. Morgan Healthcare Conference.
A strategy focused on core therapeutic areas where we have strong R&D, brands and commercial experience enables us to deliver high-value medicines that alleviate society’s greatest disease burdens. Our CEO, Vas Narasimhan provides an overview of these areas (cardiovascular, renal & metabolic, oncology, immunology and neuroscience) and the business foundations to support.
*This video uses audio from the webcasted event.*
J.P. Morgan Healthcare Conference
Event Date: January 08, 2024
Full webcast here: go.novartis.social/49012mq
Full presentation here: go.novartis.social/42lZfpC
Novartis JPM HC 2024 Coverage: go.novartis.social/3SAAJy0
Investor Relations: go.novartis.social/3SBMpjR
Investor Events: go.novartis.social/4813eJr
Novartis Strategy: go.novartis.social/3HEGx3d
Disclaimer: J.P. Morgan Healthcare Conference live event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: go.novartis.social/49dXdKx
The J.P. Morgan Healthcare conference live event also contains non-IFRS measures. An explanation of non-IFRS measures can be found on our website go.novartis.social/47UDpLa.
Learn more: go.novartis.social/3SAAJy0